Navigation Links
OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
Date:10/28/2008

VANCOUVER, British Columbia, Oct. 28 /PRNewswire-FirstCall/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), has issued a corporate profile on the Company. The OTCFN Report includes details on the ProtoKinetix technology platform, its multiple commercial applications, global target markets and management team. Interested parties can download the report at http://www.otcfn.com/pktx/pktx-report.pdf.

"Dr. Castelot-Deliencourt, chief scientist for ProtoKinetix, has achieved what was previously thought to be the impossible. She created a synthetic version of AFGP (Anti-Freeze Glycoprotein), a naturally occurring compound that enables cell survival in freezing temperatures. Her lab-created version is the industry's first stable, non-toxic and bioactive compound, even at low concentrations. Patented and trademarked by ProtoKinetix as AAGPs(TM), this revolutionary technology and its derivatives have shown to increase cellular health, survival and seem to have anti-inflammatory properties," said Geoffrey Eiten, publisher of the OTCFN Report.

"This year, ProtoKinetix entered its exciting commercial development phase, establishing partnerships with skin care manufacturers, and umbilical cord blood and health care companies to research and develop life-enhancing applications of AAGP(TM). The Company's goal is to begin generating recurring licensing revenues and royalty fees in 2009, and to increase shareholder value over the long-term," concluded Eiten.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP(TM) products. For more information, visit http://www.protokinetix.com.

OTC Financial Network serves as special advisor to ProtoKinetix Inc. and has received fees for services, including two hundred and fifty-thousand shares of restricted stock, in addition to an option to purchase two-hundred fifty-thousand shares at an exercise price of twenty cents per share, for the creation and implementation of an awareness program, including the OTC FN Report. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. A full disclaimer can be found online by visiting http://www.otcfn.com/pktx/disclaimer.html.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

CONTACT

At OTC Financial Network:

Rick McCaffrey, Investor Relations

781-444-6100 x625

rick@otcfn.com

http://www.otcfn.com/pktx

At ProtoKinetix:

Blair Henderson

604-687-9887

Email: info@protokinetix.com


'/>"/>
SOURCE ProtoKinetix Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. Avicena Group to Present at Noble Financial Conference
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Avitar Reports Third Quarter Financial Results for Fiscal 2007
7. Response Genetics Reports Second Quarter 2007 Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
10. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television ... quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global ... the challenge of how to continue to feed a growing nation. At the same ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):